Dixon B. Kaufman, MD, PhD, and colleagues examined MDR-101, an investigational cellular therapy to induce immune tolerance in kidney transplant recipients, in a phase 3 multicenter randomized trial comparing it with standard of care. The primary…
Cell Therapy Shows Potential for Reduced Immunosuppression After Kidney Transplant
